Business Context and Reporting Period
This Form 8-K Current Report from Tango Therapeutics, Inc. (TNGX) covers the 2025 Annual Meeting of Stockholders held on June 5, 2025. The meeting was conducted in a virtual-only format. As of the record date (April 8, 2025), there were 108,107,890 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders approved several key proposals at the Annual Meeting:
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares. The amendment was filed with the Delaware Secretary of State on June 5, 2025, and became effective immediately.
- Director Election: Lesley Ann Calhoun was elected as a Class I director to serve until the 2028 annual meeting.
- Auditor Ratification: PricewaterhouseCoopers, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation and determined that future advisory votes on this matter should occur annually.
Voting Participation: 96,845,552 shares were present or represented by proxy, representing 89.58% of the total shares entitled to vote, establishing a quorum.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the stockholder vote and the effective date of the charter amendment.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment (June 5, 2025) and the new authorized share count (400,000,000).
- Review the attached Exhibit 3.1 for the full legal text of the Certificate of Amendment.
- Confirm the tenure of the newly elected director, Lesley Ann Calhoun (Class I, until 2028).
- Note the shareholder mandate for annual executive compensation advisory votes.